PL3989972T3 - Agoniści receptora glukagonopodobnego peptydu 1 - Google Patents
Agoniści receptora glukagonopodobnego peptydu 1Info
- Publication number
- PL3989972T3 PL3989972T3 PL20739523.7T PL20739523T PL3989972T3 PL 3989972 T3 PL3989972 T3 PL 3989972T3 PL 20739523 T PL20739523 T PL 20739523T PL 3989972 T3 PL3989972 T3 PL 3989972T3
- Authority
- PL
- Poland
- Prior art keywords
- glucagon
- peptide
- receptor agonists
- agonists
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868117P | 2019-06-28 | 2019-06-28 | |
| US201962904906P | 2019-09-24 | 2019-09-24 | |
| PCT/US2020/038617 WO2020263695A1 (en) | 2019-06-28 | 2020-06-19 | Glucagon-like peptide 1 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3989972T3 true PL3989972T3 (pl) | 2024-03-25 |
Family
ID=71575804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20739523.7T PL3989972T3 (pl) | 2019-06-28 | 2020-06-19 | Agoniści receptora glukagonopodobnego peptydu 1 |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US11655242B2 (pl) |
| EP (2) | EP3989972B1 (pl) |
| JP (1) | JP7256300B2 (pl) |
| KR (1) | KR102738278B1 (pl) |
| CN (1) | CN114008033B (pl) |
| AU (1) | AU2020309064B2 (pl) |
| CA (1) | CA3144055C (pl) |
| CL (1) | CL2021003419A1 (pl) |
| CO (1) | CO2021017433A2 (pl) |
| CR (1) | CR20210599A (pl) |
| DK (1) | DK3989972T3 (pl) |
| DO (1) | DOP2021000273A (pl) |
| EC (1) | ECSP21093576A (pl) |
| ES (1) | ES2970173T3 (pl) |
| FI (1) | FI3989972T3 (pl) |
| HR (1) | HRP20231586T1 (pl) |
| HU (1) | HUE065080T2 (pl) |
| IL (2) | IL322973A (pl) |
| JO (1) | JOP20210337B1 (pl) |
| LT (1) | LT3989972T (pl) |
| MD (1) | MD3989972T2 (pl) |
| MX (1) | MX2021015328A (pl) |
| MY (1) | MY198745A (pl) |
| PE (1) | PE20220590A1 (pl) |
| PH (1) | PH12021553251A1 (pl) |
| PL (1) | PL3989972T3 (pl) |
| PT (1) | PT3989972T (pl) |
| RS (1) | RS64940B1 (pl) |
| SA (1) | SA521431209B1 (pl) |
| SI (1) | SI3989972T1 (pl) |
| TW (1) | TWI751585B (pl) |
| UA (1) | UA130869C2 (pl) |
| WO (1) | WO2020263695A1 (pl) |
| ZA (1) | ZA202109587B (pl) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202191432A1 (ru) | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| AU2020256647B2 (en) | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| CR20220178A (es) | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| EP4069686B1 (en) * | 2019-12-02 | 2025-01-22 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
| SI4097097T1 (sl) | 2020-01-29 | 2025-04-30 | Gilead Sciences, Inc. | Spojine, ki modulirajo glp-1r |
| PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| CN115697999A (zh) * | 2020-02-13 | 2023-02-03 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| KR102563111B1 (ko) * | 2020-03-18 | 2023-08-04 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| MX2022011349A (es) * | 2020-03-18 | 2022-11-10 | Lg Chemical Ltd | Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo. |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| WO2022052958A1 (en) | 2020-09-10 | 2022-03-17 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| WO2022111624A1 (zh) * | 2020-11-27 | 2022-06-02 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| US20240252492A1 (en) | 2021-01-28 | 2024-08-01 | Carmot Therapeutics ,Inc. | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| WO2022184849A1 (en) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
| US12180197B2 (en) | 2021-03-11 | 2024-12-31 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4317145A4 (en) * | 2021-03-24 | 2025-03-12 | Shionogi & Co., Ltd | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
| US20240300928A1 (en) * | 2021-04-08 | 2024-09-12 | Lg Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| EP4582421A3 (en) * | 2021-04-08 | 2025-10-01 | LG Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| LT4271672T (lt) | 2021-04-21 | 2026-03-10 | Gilead Sciences, Inc. | Karboksibenzimidazolo junginiai, moduliuojantys glp-1r |
| CA3217720A1 (en) * | 2021-05-03 | 2022-11-10 | Xiaohui Du | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| TWI843104B (zh) * | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| CN115703766B (zh) * | 2021-08-10 | 2025-08-08 | 天地恒一制药股份有限公司 | Glp-1受体激动剂及其用途 |
| KR20240053617A (ko) | 2021-08-30 | 2024-04-24 | 민드랭크 에이아이 리미티드 | Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물 |
| KR20240056719A (ko) | 2021-09-08 | 2024-04-30 | 시오노기 앤드 컴파니, 리미티드 | 항비만 작용이 관여하는 질환의 예방 및 치료용 의약 |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| US20250236627A1 (en) | 2021-10-05 | 2025-07-24 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057427A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| AU2023232184A1 (en) | 2022-03-08 | 2024-09-26 | Guangzhou Apichope Pharmaceutical Co., Ltd. | Benzo bicyclic compound, and preparation method and application thereof |
| CN116574092B (zh) * | 2022-05-20 | 2024-08-20 | 成都地奥九泓制药厂 | 苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用 |
| CN120379988A (zh) * | 2022-08-24 | 2025-07-25 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
| CN119907794A (zh) | 2022-09-22 | 2025-04-29 | 盐野义制药株式会社 | 具有glp-1受体激动剂作用的稠环化合物 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| CR20250178A (es) | 2022-11-16 | 2025-06-06 | Lilly Co Eli | Agonistas del receptor del péptido-1 similar al glucagón |
| KR20250168210A (ko) | 2023-02-16 | 2025-12-02 | 가셔브룸 바이오, 인크. | 헤테로시클릭 glp-1 효능제 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂，其制备方法和应用 |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| CN122055348A (zh) * | 2023-10-19 | 2026-05-15 | 伊莱利利公司 | 取代的苯乙腈及取代的苯乙酸的制备方法 |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120053180A1 (en) * | 2010-08-27 | 2012-03-01 | Chemizon, A Division Of Optomagic Co., Ltd. | Cyclohexane analogues as gpr119 agonists |
| AR087451A1 (es) * | 2011-08-17 | 2014-03-26 | Lilly Co Eli | Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes |
| WO2018098781A1 (en) * | 2016-12-01 | 2018-06-07 | Eli Lilly And Company | Pyrrolidinone compounds |
| WO2018109607A1 (en) * | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CA3045644C (en) | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| FI3806855T3 (fi) | 2018-06-15 | 2023-05-04 | Pfizer | Glp-1 -reseptorin agonisteja ja niiden käyttöjä |
| EA202191432A1 (ru) * | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| AU2020256647B2 (en) * | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| WO2021018023A1 (zh) | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| CR20220178A (es) * | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| ES3029360T3 (en) | 2019-11-15 | 2025-06-24 | Ildong Pharmaceutical Co Ltd | Glp-1 receptor agonist and use thereof |
| EP4069686B1 (en) | 2019-12-02 | 2025-01-22 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
| SI4097097T1 (sl) | 2020-01-29 | 2025-04-30 | Gilead Sciences, Inc. | Spojine, ki modulirajo glp-1r |
| CN115697999A (zh) | 2020-02-13 | 2023-02-03 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| MX2022011349A (es) * | 2020-03-18 | 2022-11-10 | Lg Chemical Ltd | Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo. |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
-
2020
- 2020-06-17 TW TW109120333A patent/TWI751585B/zh active
- 2020-06-19 CA CA3144055A patent/CA3144055C/en active Active
- 2020-06-19 UA UAA202106794A patent/UA130869C2/uk unknown
- 2020-06-19 HR HRP20231586TT patent/HRP20231586T1/hr unknown
- 2020-06-19 RS RS20231184A patent/RS64940B1/sr unknown
- 2020-06-19 EP EP20739523.7A patent/EP3989972B1/en active Active
- 2020-06-19 MY MYPI2021007760A patent/MY198745A/en unknown
- 2020-06-19 JP JP2021577551A patent/JP7256300B2/ja active Active
- 2020-06-19 KR KR1020217042363A patent/KR102738278B1/ko active Active
- 2020-06-19 ES ES20739523T patent/ES2970173T3/es active Active
- 2020-06-19 DK DK20739523.7T patent/DK3989972T3/da active
- 2020-06-19 PL PL20739523.7T patent/PL3989972T3/pl unknown
- 2020-06-19 PH PH1/2021/553251A patent/PH12021553251A1/en unknown
- 2020-06-19 CR CR20210599A patent/CR20210599A/es unknown
- 2020-06-19 WO PCT/US2020/038617 patent/WO2020263695A1/en not_active Ceased
- 2020-06-19 MX MX2021015328A patent/MX2021015328A/es unknown
- 2020-06-19 PE PE2021002176A patent/PE20220590A1/es unknown
- 2020-06-19 IL IL322973A patent/IL322973A/en unknown
- 2020-06-19 HU HUE20739523A patent/HUE065080T2/hu unknown
- 2020-06-19 LT LTEPPCT/US2020/038617T patent/LT3989972T/lt unknown
- 2020-06-19 EP EP23206307.3A patent/EP4302826A3/en not_active Withdrawn
- 2020-06-19 CN CN202080046428.3A patent/CN114008033B/zh active Active
- 2020-06-19 PT PT207395237T patent/PT3989972T/pt unknown
- 2020-06-19 MD MDE20220509T patent/MD3989972T2/ro unknown
- 2020-06-19 FI FIEP20739523.7T patent/FI3989972T3/fi active
- 2020-06-19 AU AU2020309064A patent/AU2020309064B2/en active Active
- 2020-06-19 SI SI202030314T patent/SI3989972T1/sl unknown
- 2020-06-19 US US16/906,063 patent/US11655242B2/en active Active
-
2021
- 2021-11-25 ZA ZA2021/09587A patent/ZA202109587B/en unknown
- 2021-11-28 IL IL288479A patent/IL288479B2/en unknown
- 2021-12-20 CO CONC2021/0017433A patent/CO2021017433A2/es unknown
- 2021-12-20 CL CL2021003419A patent/CL2021003419A1/es unknown
- 2021-12-23 DO DO2021000273A patent/DOP2021000273A/es unknown
- 2021-12-26 JO JOJO/P/2021/0337A patent/JOP20210337B1/ar active
- 2021-12-26 SA SA521431209A patent/SA521431209B1/ar unknown
- 2021-12-28 EC ECSENADI202193576A patent/ECSP21093576A/es unknown
-
2023
- 2023-03-31 US US18/194,155 patent/US20230250092A1/en not_active Abandoned
-
2024
- 2024-09-09 US US18/828,945 patent/US20250002482A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288479B1 (en) | Glucagon-like peptide-1 receptor agonists | |
| ZA202006115B (en) | Phenylpyrrolidinone formyl peptide 2 receptor agonists | |
| PL4069686T3 (pl) | Agonista receptora glp-1 | |
| IL279300A (en) | 1-GLP agonist receptors and their use | |
| IL279224A (en) | 1-GLP agonist receptors and their use | |
| PL4058445T3 (pl) | Agonista receptora glp‑1 i jego zastosowanie | |
| IL273253A (en) | Glucagon-like peptide-1 receptor agonists and their uses | |
| SG11202013044PA (en) | Il2 agonists | |
| IL308397A (en) | Macrocyclic glucagon-like peptide 1 receptor agonists | |
| SG11202106257WA (en) | Chimeric receptor polypeptides and uses thereof | |
| GB201816639D0 (en) | GLP-1 Receptor Antagonist | |
| MA56391A (fr) | Agonistes du récepteur du peptide de type glucagon 1 | |
| HK40023936A (en) | Glucagon-like peptide 1 receptor agonists and uses thereof | |
| GB201910515D0 (en) | GLP-1 Receptor antagonists | |
| GB202316884D0 (en) | Glucagon-like peptide 1 agonists | |
| GB201816650D0 (en) | GLP-1 Receptor antagonists | |
| GB201817943D0 (en) | Galanin-2 receptor agonists | |
| GB202007050D0 (en) | Peptide agonist | |
| GB201917927D0 (en) | Factor VIII polypeptide | |
| GB201911708D0 (en) | Polypeptides | |
| GB201903985D0 (en) | GLP receptor agonists | |
| GB201914099D0 (en) | Swivel joint |